Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Vile

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|September 20, 2025
Oncolytic viruses as anticancer agents: clinical progress and remaining challengesElizabeth Appleton, E Antonio Chiocca, Guy Ungerechts, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 20, 2009
Cell carriers for oncolytic viruses: Fed Ex for cancer therapyCandice Willmon, Kevin Harrington, Timothy Kottke, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 12, 2002
Dendritic cells for the immunotherapy of cancerAlan Melcher, Andrew Bateman, Kevin Harrington, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2003
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effectXinping Fu, Lihua Tao, Aiwu Jin, et al.
Cancer Immunology, Immunotherapy : CII|December 7, 2007
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapyAlison Merrick, Rosa Maria Diaz, Dearbhaile O'Donnell, et al.
Transactions of the American Ophthalmological Society|February 4, 2010
Infiltrative T regulatory cells in enucleated uveal melanomasEvan Lagouros, Diva Salomao, Erik Thorland, et al.
Human Gene Therapy|June 28, 2012
Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escapeKaren M Kaluza, Timothy Kottke, Rosa Maria Diaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 21, 2010
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signalingPhonphimon Wongthida, Rosa M Diaz, Feorillo Galivo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2005
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapyMichael Gough, Marka Crittenden, Uma Thanarajasingam, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2008
Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapyPaul Hatfield, Alison E Merrick, Emma West, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|September 20, 2025
Oncolytic viruses as anticancer agents: clinical progress and remaining challengesElizabeth Appleton, E Antonio Chiocca, Guy Ungerechts, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 20, 2009
Cell carriers for oncolytic viruses: Fed Ex for cancer therapyCandice Willmon, Kevin Harrington, Timothy Kottke, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 12, 2002
Dendritic cells for the immunotherapy of cancerAlan Melcher, Andrew Bateman, Kevin Harrington, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2003
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effectXinping Fu, Lihua Tao, Aiwu Jin, et al.
Cancer Immunology, Immunotherapy : CII|December 7, 2007
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapyAlison Merrick, Rosa Maria Diaz, Dearbhaile O'Donnell, et al.
Transactions of the American Ophthalmological Society|February 4, 2010
Infiltrative T regulatory cells in enucleated uveal melanomasEvan Lagouros, Diva Salomao, Erik Thorland, et al.
Human Gene Therapy|June 28, 2012
Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escapeKaren M Kaluza, Timothy Kottke, Rosa Maria Diaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 21, 2010
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signalingPhonphimon Wongthida, Rosa M Diaz, Feorillo Galivo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2005
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapyMichael Gough, Marka Crittenden, Uma Thanarajasingam, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2008
Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapyPaul Hatfield, Alison E Merrick, Emma West, et al.
Pageof 10